The MarketReader Minute
💊 Moderna Falls on Downgrades and R&D Cuts, While BioNTech and Halozyme Surge Amid FDA Approvals and Clinical Advances | Biotech Sector Insights
Notably, BioNTech (BNTX) has contributed positively with a substantial return, amidst a mix of bearish and bullish options trading activity. Analyst ratings for BNTX reflect a consensus price target around $105.67.